Sarasota-based Dickinson & Gibbons attorneys named Florida Super Lawyers
The rating service identifies lawyers who have attained a high degree of peer recognition and professional achievement. The annual selections involve independent research by Super Lawyers and evaluations from a highly credentialed panel of attorneys.
Blue specializes in marital and family law cases involving equitable distribution, business valuation, alimony, child support, parental responsibility, prenuptial and postnuptial agreements, paternity, and other related matters. This is her 18th year as a Florida Super Lawyer.
Larsen mediates in all areas of civil litigation, including medical malpractice, wrongful death, personal injury, probate, construction, business, professional malpractice, employment, real estate, product liability, and insurance coverage disputes. This is his 12th year as a Super Lawyer.
Peairs specializes in litigation matters, including personal injury, motor vehicle negligence, wrongful death, trucking and transportation, product liability, insurance coverage, and construction.
Butler, a member of the Florida Bar Board of Governors, focuses on cases involving legal malpractice, deceptive and unfair trade practices, consumer law, and general civil and business litigation.
A new charitable foundation to support individuals affected by HIV was founded on July 1 by Tampa-based CAN Community Health and honors Sarasota AIDS advocate Susan Terry, who founded Sarasota's first AIDS clinic in 1991.
"Susan Terry's name is synonymous with compassion,' said Rishi Patel, president and CEO of CAN Community Health. 'This Foundation honors her by helping patients overcome real-life obstacles, because true wellness means meeting people where they are, and being there when they need us.'
In the early 1990s, Terry joined Dr. Jeffrey Stahl to establish the Comprehensive Care Center dedicated to treating AIDS patients. It later became the Community AIDS Network, paving the way for CAN Community Health. Terry died in 2009.
'The Susan Terry Foundation launched to bring together individuals, corporations and foundations interested in helping to create a future where individuals living with HIV are celebrated for their resilience and empowered to achieve their dreams,' said Ray Carson, executive director of the foundation.
For more information, including how to get involved, visit susanterryfoundation.org or contact Carson at 813-300-6555 or info@susanterryfoundation.org.
Goodwill Manasota recently received a three-year grant totaling $192,000 from United Way Suncoast in support of financial literacy training.
The funds will support operational costs related to Goodwill's GoodPartner Coach and Learning and Development programs. Over the next three years, Goodwill leaders expect to impact 1,400 people – a combination of employees and community members seeking assistance at Goodwill's Community Resource Centers/Job Connection sites in Sarasota, Manatee and DeSoto counties.
'This funding cycle marks a major step forward in both equity and effectiveness,' United Way Suncoast CEO Jessica Muroff said. 'By focusing on sustained, multiyear investments, we're helping our partners build capacity, deliver measurable results, and better serve ALICE [Asset Limited, Income Constrained, Employed] families across the region.'
The Clerk of the Circuit Court & Comptroller for Manatee County was recently honored by the Florida Court Clerks & Comptrollers' Best Practices Excellence Program for the fifth consecutive year.
The Office of Angelina 'Angel' Colonneso was one of 33 out of 59 to earn recognition in all 10 program categories this year. The FCCC's Best Practices Program promotes guidance, legal consistency, and operational excellence through a series of self-assessments and peer-reviewed evaluations. ... July 21 is the deadline for small businesses and private nonprofits to apply for low interest federal disaster loans to offset economic losses caused by Hurricane Debby in August 2024, the U.S. Small Business Administration said. ... Jolyn Taylor, Cody Pleszewski, Juan Casique, Kody Donato, Crystal Joguilon, Dana Musco and Christine Dinerstein have joined EXIT King Realty at 8728 E. State Road 70 in Bradenton. Buki Kodra has joined the independently owned and operated brokerage at 3900 Clark Road in Sarasota. .... Sarasota's Finest Home Watch has earned accreditation from the National Home Watch Association. Linda DeNiro, a retired Sarasota police detective, founded the business in 2022.
Compiled from news releases
This article originally appeared on Sarasota Herald-Tribune: Sarasota-based Dickinson & Gibbons attorneys named Super Lawyers
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
ViiV's HIV shot preferred, as activists spotlight funding crisis at IAS 2025
ViiV Healthcare's combination injectable human immunodeficiency virus (HIV) medication was preferred over a daily tablet in treatment-naïve patients in a Phase IIIb trial. A global specialist in HIV that is majority owned by GSK, with Pfizer and Shionogi as shareholders, ViiV announced data from the Phase IIIb VOLITION study (NCT05917509) at the International AIDS Society (IAS) conference 2025, taking place from 13 to 15 July in Kigali, Rwanda. In the study, 89% of treatment-naïve HIV patients switched to Cabenuva (a combination treatment of cabotegravir and rilpivirine) following rapid viral suppression with daily Dovato (dolutegravir/lamivudine). Cabenuva is dosed once every two months by a healthcare professional. Patients were initially treated with daily Dovato until they achieved viral suppression. At this point, they were offered the opportunity to change to Cabenuva. The most common reasons cited for choosing Cabenuva were not having to worry about missing a dose each day (80%) and not having to carry medication (68%). ViiV CMO Jean van Wyk said: 'Long-acting injectables provide options that can offer high effectiveness and tolerability, improved adherence, and a preferred dosing schedule compared with daily oral pills. We believe they are a key part of HIV treatment and prevention and will play a critical role in achieving our ambition of ending HIV and AIDS.' Patients were initially treated with daily Dovato until they achieved viral suppression. At this point, they were offered the opportunity to change to Cabenuva. Effectiveness was also sustained with Cabenuva in the real world, with data from several observational studies. In these studies, Cabenuva was shown to address challenges associated with daily oral pills, offering improved treatment satisfaction, high effectiveness and a patient-preferred treatment option that supports long-term virologic control. It also provides better adherence to treatment, something which is a real issue with daily PrEP options due to stigma concerns. GlobalData, the parent company of Clinical Trials Arena, predicts sales of Cabenuva to reach $2.83bn in 2030. ViiV is also investigating an HIV therapy that can be dosed once every four months. In a Phase IIb trial, the therapy was able to suppress viral load below 50 copies per millimetre in blood. Long-acting pre-exposure prophylaxis (PrEP) for HIV has been prominent on the agenda at the IAS 2025 meeting. MSD has initiated two Phase III studies of its monthly oral PrEP candidate, and Gilead is set to report more positive data from its two-Phase III studies of twice-yearly Yeztugo (lenacapavir). On 14 July, the World Health Organization (WHO) endorsed the use of Yeztugo, saying that without a vaccine, it is the 'next best thing'. GlobalData analysts highlighted that the approval of Yeztugo is a 'momentous step in improving PrEP options available for people vulnerable to contracting HIV'. The main topic of conversation at the IAS 2025 conference, however, is the loss of various funding schemes which helped to provide treatment and research into HIV. Funding cuts by Trump's administration are already impacting low-income and middle-income countries, with cases of HIV already rising just six months after the reductions were made. During IAS's opening session, a group of activists took to the stage to vocalise their anger at the loss of funding, as well as some companies removing their diversity policies that recognised patients from LGBTQ+ communities, many of whom are more susceptible to transmitting HIV. The activists chanted 'we will not be erased' as they took to the stage, with several members of the group sharing their views and experiences as HIV patients from the LGBTQ+ community. The conference states it is welcoming of protests and that it 'endorses freedom of speech as an essential principle to end the HIV pandemic as a threat to public health'. "ViiV's HIV shot preferred, as activists spotlight funding crisis at IAS 2025" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
an hour ago
- Yahoo
What to Expect From Hologic's Q3 2025 Earnings Report
Marlborough, Massachusetts-based Hologic, Inc. (HOLX) develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health, focusing on early detection and treatment worldwide. With a market cap of $14.4 billion, the company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. HOLX is all geared up for its fiscal Q3 2025 results after the market closes on Wednesday, Jul. 30. Before this event, analysts project this company to report an adjusted EPS of $1.05, down marginally from $1.06 in the year-ago quarter. The company has surpassed Wall Street's bottom-line estimates in three of the last four quarters, while falling short in one quarter. Palantir Just Launched Warp Speed for Warships. Does That Make PLTR Stock a Buy? This Analyst Just Doubled His Price Target on AMD Stock How High Can Nvidia Stock Go as Jensen Huang Heads to China? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! For fiscal 2025, analysts expect HOLX to report an adjusted EPS of $4.19, representing a 2.7% year-over-year increase from $4.08 in fiscal 2024. Moreover, in fiscal 2026, the company's adjusted EPS is expected to increase 7.4% year-over-year to $4.50. HOLX stock has declined 16.8% over the past 52 weeks, lagging behind both the S&P 500 Index's ($SPX) 11.6% gain and the Health Care Select Sector SPDR Fund's (XLV) 8.6% decline over the same time frame. On May 1, HOLX stock dropped 1.6% following the release of its Q2 2025 results. The company's revenue declined 1.2% year-over-year, primarily due to a decrease in breast health revenue resulting from lower sales of mammography capital equipment. Moreover, its adjusted EPS for the quarter came in at $1.03, surpassing the consensus estimates marginally. Analysts are moderately optimistic about HOLX's stock, with an overall "Moderate Buy" rating. Among 19 analysts covering the stock, six recommend "Strong Buy," one suggests a 'Moderate Buy,' and 12 advise 'Hold.' The mean price target of $68.67 indicates a 6.3% potential upside from HOLX's current price levels. On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
News24
2 hours ago
- News24
SA gets R520m to buy the twice-a-year anti-HIV jab... but there's a snag
SA has accepted an offer of just over $29 million from the Global Fund to Fight Aids, TB and Malaria to buy the twice-a-year anti-HIV jab, lenacapavir. . But there's a snag: the country isn't getting extra money from the fund to buy the medicine. It has to use cash from a grant that it has already been awarded and that was cut by 16% in June. South Africa has accepted an offer of just over $29 million (about R520 million) from the Global Fund to Fight Aids, TB and Malaria to buy the twice-a-year anti-HIV jab, lenacapavir, that research shows could help to end Aids in the country, says health department spokesperson Foster Mohale. But there's a snag. The country isn't getting extra money from the fund to buy the medicine; it has to use cash from a grant that it has already been awarded and that was cut by 16% in June. Moreover, the fund, at this stage, won't tell the health department – or any of the other eight countries it has selected for early roll-out – how much they're paying lenacapavir's maker, Gilead Sciences, for the product. Boitumelo Semete-Makokotlela, the CEO of the country's medicine regulator, the South African Health Products Regulatory Authority (Sahpra), told Bhekisisa it is aiming to have lenacapavir registered in South Africa before the end of the year. According to the national health department's head of procurement, Khadija Jamaloodien, the lenacapavir funds from the Global Fund will become available in October, when the rollout period of South Africa's next grant, known as Grant Cycle 7, kicks in. But rollout – likely in early 2026 – can only start once Sahpra has registered the medicine, the country's essential medicines list committee has reviewed and recommended lenacapavir, procurement processes are in place and health workers and clinics have all they need to hand the drug safely to patients. Two studies released last year showed the medicine completely protects young women from contracting the virus and works almost as well for men, transgender and gender-nonbinary people. In fact, a modelling study shows that if between two and four million HIV-negative people in South Africa use the jab every year over the next eight years, the medication could end Aids as a public health threat by 2032. Ending Aids as a public health threat means reaching a stage where fewer people are getting newly infected with HIV than the number of people with HIV who are dying (increasingly for other reasons than HIV, for example old age). According to the latest Joint United Nations Programme on HIV and Aids (UNAids) report, which was released last week, 170 000 people got newly infected with HIV in 2024, while there were 53 000 Aids-related deaths. The Global Fund money for South Africa is, however, not nearly enough to put two to four million people per year in South Africa on the lenacapavir jab (see price explanation below) – and even if it was, the country's health system won't be able to roll the medicine out that fast, scientists and policymakers say. Will the US help to pay for the jab? The fund's offer follows the body's announcement on 9 July, that it has the 'ambition' to finance enough lenacapavir for two million HIV-negative people – in the low- and middle-income countries it supports – over the next three years. But fulfilling this ambition will depend on whether the governments of wealthy countries give enough money to the fund in its next replenishment round. The US government's Aids fund, Pepfar, was originally going to help to pay to roll out lenacapavir in poorer countries. And, although some activists say it's still possible for the US administration to come on board (lenacapavir is mentioned in President Donald Trump's budget proposal for the next financial year, but is understood to be only for pregnant and breastfeeding women), it's not clear at all how this might happen after the Trump administration's drastic cuts to funding for HIV projects in countries like South Africa this year. The Global Fund's offer, however, is a way to get branded, 'bridging' doses from Gilead to South Africa while the world waits for cheaper generics to become available around 2027. 'We now stand at a moment of reckoning and a moment of choice,' Mitchell Warren, the executive director of the international advocacy organisation, Avac, told Bhekisisa at the 13th conference on HIV science in Kigali this week. 'While a lot of the choices over the last six months have been made by an American politician [Donald Trump] who doesn't care about the pandemic or science generally, our choice is to make decisions based on the science that we all now know. Which is that lenacapavir is our most potent opportunity.' Countries have to budget just under R600 per dose Jamaloodien, however, cautions further discussions with the Global Fund and Gilead will be needed about the governance around the pricing of the product. 'We have a transparent pricing system, guided by the Public Finance Management Act. Even if we procure medicine with Global Fund money, we have to follow the same rules that the Treasury requires us to follow with tenders, which includes revealing the price at which the medicine is bought,' Jamaloodien says. In a Global Fund letter sent in early July to the nine early rollout countries – South Africa, Zimbabwe, Eswatini, Lesotho, Zambia, Mozambique, Kenya, Uganda and Nigeria – the fund asked the governments to budget for $60 (about R1 076) per patient per year ($30, or R576, per six-monthly dose), to buy lenacapavir. But in the document, which Bhekisisa has seen, the fund makes it clear that the amount 'reflects the country contribution only, to be used for budgeting purposes, and should not be considered the product price'. Jamaloodien has confirmed to Bhekisisa that the health department did receive such a letter. The letter also states that the gap between the price that the fund pays Gilead per patient per year and the $60 that countries will pay for with their Global Fund grants, will be covered by private sector funding, which Hui Yang, the fund's head of supply operations, confirmed to Bhekisisa will be paid for by a $150-million (about R2.68 billion) donation of the UK-based Children's Investment Fund Foundation to the Global Fund. Furthermore, says Jamaloodien, South Africa's letter instructs the country to submit its first order, for planning purposes, by 30 September under an 'agreed procurement mechanism'. Why does Gilead not want to talk about LEN's price? Lenacapavir, also referred to as LEN for short, was registered for HIV prevention – also called PrEP – by the US medicines regulator, the Food and Drug Administration on 18 June, and is sold in that country for $28 218 (around R505 269) per person per year under the trade name Yeztugo. The US is the only country in which LEN has been registered so far as PrEP. For low- and middle-income countries such as South Africa, Gilead, however, said it will have a 'not-for-profit' price such as the one they negotiated with the Global Fund, but isn't allowing the fund to make it public. Several scientists and activists at the HIV science conference, have, however, told Bhekisisa the rumoured not-for-profit price that Gilead has negotiated with the Global Fund is $100 per person per year, and Avac, confirms it in its analysis of events. But neither Gilead or the Global Fund have confirmed this amount. If South Africa budgets for $60 per person per year, the $29.2 million that Global Fund says we can use to buy lenacapavir, translates to putting and keeping around 400 000 people on the medicine over three years (Global Fund grants run for three years at a time). Gilead argues that because the not-for-profit price is based on the actual cost of making lenacapavir, and shipping it to countries, it can't declare that cost. 'Gilead doesn't publicly disclose manufacturing costs for any of our medications,' Caroline Almeida, Gilead's head of public affairs, told Bhekisisa in Kigali. But activists don't buy this argument. 'Gilead's secrecy will obstruct civil society activism for lower drug prices and keep prices high in middle-income countries [such as South Africa] where Gilead negotiates prices directly,' the Health Justice Initiative and other activist groups said in a press release last week. Avac has identified 16 top lenacapavir markets, of which South Africa is – by far – the largest because of the country's high number of new HIV infections. The country's 170 000 new infections in 2024 is 13% of the 1.3 million new HIV infections around the world in 2024. And research released by Wits RHI on Tuesday in Kigali shows South Africans are open to using the jab: 56% of just over 1 700 participants in a survey in Tshwane, Mthatha and Gqeberha, who were already using public sector HIV prevention services, said they would take a lenacapavir shot. But for LEN to be affordable, activists argue, Gilead needs to be open about its price. 'Such secrecy undermines the power of buyers to negotiate affordable prices and violates the human rights of all people to access information and lifesaving tools,' activists said in last week's press release. Warren concludes: 'Pricing transparency has been a long-standing challenge, as companies try to balance their commercial pricing and marketing strategies with their global public health strategies. We clearly need a new model or compact for pricing that helps break the cycle of small thinking and limited impact.'
